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Abstract
Our previous studies have shown that benzyl isothiocyanate (BITC) suppresses pancreatic tumor growth by inhibiting STAT-
3; however, the exact mechanism of tumor growth suppression was not clear. Here we evaluated the effects and
mechanism of BITC on pancreatic tumor angiogenesis. Our results reveal that BITC significantly inhibits neovasularization on
rat aorta and Chicken-Chorioallantoic membrane. Furthermore, BITC blocks the migration and invasion of BxPC-3 and PanC-
1 pancreatic cancer cells in a dose dependant manner. Moreover, secretion of VEGF and MMP-2 in normoxic and hypoxic
BxPC-3 and PanC-1 cells was significantly suppressed by BITC. Both VEGF and MMP-2 play a critical role in angiogenesis and
metastasis. Our results reveal that BITC significantly suppresses the phosphorylation of VEGFR-2 (Tyr-1175), and expression
of HIF-a. Rho-GTPases, which are regulated by VEGF play a crucial role in pancreatic cancer progression. BITC treatment
reduced the expression of RhoC whereas up-regulated the expression of tumor suppressor RhoB. STAT-3 over-expression or
IL-6 treatment significantly induced HIF-1a and VEGF expression; however, BITC substantially suppressed STAT-3 as well as
STAT-3-induced HIF-1a and VEGF expression. Finally, in vivo tumor growth and matrigel-plug assay show reduced tumor
growth and substantial reduction of hemoglobin content in the matrigel plugs and tumors of mice treated orally with
12 mmol BITC, indicating reduced tumor angiogenesis. Immunoblotting of BITC treated tumors show reduced expression of
STAT-3 phosphorylation (Tyr-705), HIF-a, VEGFR-2, VEGF, MMP-2, CD31 and RhoC. Taken together, our results suggest that
BITC suppresses pancreatic tumor growth by inhibiting tumor angiogenesis through STAT-3-dependant pathway.
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Introduction
The prognosis for patients with advanced pancreatic cancer
remains poor with a median survival of only 6 months, making it
the fourth leading cause of cancer-related deaths in both men and
women [1,2]. Minimal effect of conventional chemotherapy drugs,
including gemcitabine, on patient survival rates underscores the
need for new strategies to inhibit pancreatic tumor growth [3].
Pancreatic tumors can trigger substantial development of new
blood vessels in a process called angiogenesis. This vascular
development is a necessary component of solid tumor growth and
progression [4]. Numerous reports have shown that disrupting
tumor angiogenesis effectively inhibits tumor growth and metas-
tasis [5,6,7].
Various stimuli such as hypoxia, inflammation, and mechanical
stress and stretch are known to initiate angiogenesis [8]. Critical
steps of angiogenesis including migration, invasion, and prolifer-
ation are mediated by complex signaling proteins such as hypoxia
inducible factor (HIF-a), vascular endothelial growth factor
(VEGF), and matrix metalloproteinases (MMPs) [8]. During
hypoxia, HIF-a protein levels increase due to a decreased rate
of ubiquitin-mediated degradation [9]. Up-regulation of the HIF-1
system is observed in many cancers and is caused by multiple
genetic and environmental factors [10]. VEGF expression is
regulated by HIF-1a-dependent and -independent mechanisms
[11]. Recent studies have identified the signal transducer and
activator of transcription 3 (STAT-3) as a direct transcriptional
activator of VEGF and HIF-1a under hypoxia [12,13]. Moreover,
constitutive activation of STAT-3 occurs at a frequency of 50–
90% in a broad range of human cancers, suggesting that STAT-3
activity contributes significantly to tumor VEGF overproduction
[12]. Previous reports have shown that phosphorylated STAT-3 is
associated with over-expression of VEGF and HIF-1a in human
pancreatic tumors and that inhibition of STAT-3 causes significant
reduction in tumor growth and vascularization [14]. Recent
reports show that Rho-GTPases, which are downstream of VEGF
signaling, play a vital role in all stages of cancer progression,
including metastasis [15,16]. Thus, the disruption of tumor
angiogenesis resulting from the inhibition of STAT-3, HIF-a/
VEGF/Rho-GTPases, and MMPs production represents a
promising strategy for cancer therapy.
Case-controlled epidemiological studies continue to support the
notion that consumption of cruciferous vegetables reduces the risk
of pancreatic cancer [17,18]. Benzyl isothiocyanate (BITC) present
in cruciferous vegetables such as watercress and garden cress
inhibits chemically-induced cancers in experimental animals
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25799[19,20]. Previous studies, including those from our laboratory,
have shown that BITC effectively suppresses the growth of human
pancreatic cancer cells both in vitro and in vivo by causing apoptotic
cell death through MAPK activation or NF-kB inhibition
[21,22,23,24]. Our previous studies have demonstrated that BITC
suppresses pancreatic tumor growth by inhibiting STAT-3 [23].
We also have shown that normal human pancreatic epithelial cells
were least affected by BITC treatment [22,23,24]. However, it still
is not clear if BITC suppresses pancreatic tumor progression by
inhibiting tumor angiogenesis. Therefore, this study evaluated the
effect of BITC on pancreatic tumor angiogenesis and investigated
the underlying molecular mechanism. We provide evidence that
BITC dose-dependently inhibits the migration, invasion, and
neovascularization of human pancreatic cancer and endothelial
cells by targeting HIF1a, VEGF, MMP-2, and Rho-GTPases
through the STAT-3 dependent pathway.
Results
Inhibition of neovascularization by BITC
To address whether BITC inhibits angiogenesis, rat aortic rings
embedded in matrigel were incubated with different concentra-
tions of BITC. Aortic sprouting was initiated by treating the rings
with 20 ng/mL VEGF. Treatment with 5 mM BITC reduced
sprouting of new blood vessels by 67% as compared to control
aortic rings (Fig. 1A). The area under the sprout outside the
treated rings (845 mm
2) was reduced by 91% as compared to
control rings (9747 mm
2) (Fig. 1B).
To confirm the observations made in rat aortic ring assay, we
examined the effect of BITC on CAM angiogenesis. As shown in
Fig. 1C, 5 mmol BITC treatment drastically suppressed new
embryonic blood vessel growth in each egg as compared to control
eggs. The number of newly formed blood vessels was suppressed
Figure 1. BITC inhibits angiogenesis ex vivo.A . BITC inhibits VEGF-induced vessel sprouting ex vivo. Aortic rings (1 mm) were harvested from
Sprague-Dawley rats, immerged in matrigel, and treated with VEGF (20 ng/mL) in the absence or presence of BITC (0, 2.5 and 5 and 10 mM) for 4 days
and photographed under microscope (4X). Representative photographs are presented. B. Quantitative analysis of aortic ring assay. Aortic ring
sprouting was quantified by Image J software and presented as mean 6 SD of triplicates. C. Inhibition of CAM angiogenesis by BITC. Eggs were
incubated at 37uC for 3 days. A Whatman filter disc containing the test compound (BITC 5 mmol) was placed on the CAM of eggs (n=10) through pre-
opened window and further incubated. On day 9–12 of incubation, photographs were made after removing the filter discs. A representative
photograph is presented. D. Blood vessels density was quantified by Image J software and represented as a bar diagram.
doi:10.1371/journal.pone.0025799.g001
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CAMs (Fig. 1C & D).
BITC inhibits secretion of MMP-2 and VEGF from
pancreatic tumor cells under normoxic and hypoxic
conditions
In the tumor microenvironment, migration, invasion, and
neovascularization are critically regulated by proangiogenic factors
such as VEGF and MMP-2 secreted by tumor cells [25,26].
Therefore, we next examined whether BITC suppresses the
secretion of VEGF and MMP-2 from BxPC-3 and PanC-1
pancreatic tumor cells. BITC treatment significantly inhibited
secreted levels of VEGF in both cell lines in a dose-dependent
manner. Treatment with 10 mM BITC inhibited VEGF levels in
the BxPC-3 cells by about 64% and in the PanC-1 cell by about
53% (Fig. 2A–2B). Similarly, 10 mM of BITC inhibited MMP-2
secretion in BxPC-3 cells by 79% and in PanC-1 cells by 60%.
(Fig. 2C–2D).
Since we observed that BITC blocked the secretion of VEGF and
MMP-2 in BxPC-3 and PanC-1 cells under normoxic conditions,
we next sought to determine whether BITC causes a similar effect
under hypoxic conditions. Our results show that VEGF secretion
increased approximately 2 fold (Fig. 2A) and MMP-2 levels
increased around 3.5 fold in hypoxic BxPC-3 cells, as compared
to normoxic cells. These observations were consistent with previous
reports showing increased secretion of VEGF and MMP-2 under
hypoxic conditions [27]. In both BxPC-3 and PanC-1 cells,
hypoxia-induced enhanced VEGF and MMP-2 secretion levels
were substantially reduced by BITC in a dose-dependent manner
(Fig. 2A–2D). For example, 10 mM BITC inhibited 70% and 51%
of VEGF secretion and 60% and 44% of MMP-2 secretion by
BxPC-3 and PanC-1 cells respectively, as compared to hypoxic
control cells.
Figure 2. BITC inhibits secretion of proangiogenic factors from BxPC-3 and PanC-1 cells under normoxic and hypoxic conditions.
Serum-starved BxPC-3 or PanC-1 cells were treated with various concentrations of BITC in a 96-well plate and incubated for 24 h. For hypoxia
treatment, cells were exposed to 1% pO2 for 24 h. Culture supernatants were collected and assayed for MMP-2 or VEGF by ELISA kit -. A–B. BITC
suppresses secretion of VEGF from BxPC-3 and PanC-1 cells. C–D. BITC blocks secretion of MMP-2. Values are mean 6 SD of triplicates. *p,0.01
statistically significant when compared with normoxic controls. #p,0.01, statistically significant when compared with hypoxic controls.
doi:10.1371/journal.pone.0025799.g002
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To explore the molecular mechanism of the antiangiogenic
effects of BITC, BxPC-3 and PanC-1 cells were immunoblotted
for various pro-angiogenic proteins. Our results indicate that
BITC significantly reduced hypoxia-induced HIF-1a expression
in both BxPC-3 and PanC-1 cells (Fig. 3A). Furthermore, our
results reveal that BITC significantly down-regulated the
expression and the phosphorylation (activation) of VEGFR-2
(Tyr-1175) as well as the expression of VEGF and MMP-2 in
both BxPC-3 and PanC-1 cells (Fig. 3A). To examine whether
down regulation of VEGFR-2 and/or MMP-2 expression by
BITC was at the transcriptional level, mRNA was analyzed by
RT-PCR. Our results reveal that mRNA levels of both VEGFR-2
and MMP-2 were reduced significantly in both the cell lines in
response to treatment (Fig. 3B), indicating that BITC inhibits
both VEGF and MMP-2 at the transcriptional level. To further
delineate the mechanism, cell lysates were probed for VEGFR-2
downstream proteins such as Rho-GTPases, which play a critical
role in cancer progression and metastasis. Our results demon-
strate that the expression of RhoA, RhoC, Cdc-42, and Rac 1,2,3
were significantly reduced by BITC treatment, whereas RhoB
expression levels were up-regulated in BxPC-3 and PanC-1 cells
in a dose-dependent manner (Fig. 3A).
BITC suppresses STAT-3 mediated induction of HIF-1a
and VEGF expression
Previous reports have identified STAT-3 as a direct transcrip-
tional activator of HIF-1a and VEGF during hypoxia [12,13]. We
therefore wanted to see whether inhibition of HIF-1a and VEGF
by BITC was mediated through STAT-3. To address this
question, BxPC-3 cells were treated with IL-6, which specifically
activates STAT-3 by phosphorylation at Tyr-705, and determined
HIF-1a and VEGF expression. Our results show that IL-6
drastically increased the expression of HIF-1a and VEGF in
BxPC-3 cells. When these cells were treated with BITC, IL-6-
induced HIF-1a and VEGF expression was substantially reduced
(Fig. 3C). These results indicate that BITC inhibits HIF-1a and
VEGF through STAT-3 dependent pathway.
STAT-3 is obligatory for BITC mediated HIF-1a and VEGF
inhibition
To further confirm the involvement of STAT-3 in BITC
mediated HIF-1a and VEGF inhibition, STAT-3 was either
transiently over-expressed or silenced in BxPC-3 cells. Our results
show that over-expression of STAT-3 in BxPC-3 cells significantly
increased the expression of HIF-1a and VEGF under hypoxia
(Fig. 3D). On the other hand, silencing STAT-3 with shRNA in
BxPC-3 cells showed a modest decrease in the expression of HIF-
1a and VEGF as compared to control cells under hypoxia
(Fig. 3D). Similar observations were made in STAT-3 stably
knocked out BxPC-3 cells (Fig. 3D), indicating the pivotal role of
STAT-3 in hypoxia-induced HIF-1a and VEGF expression.
When STAT-3 over-expressing BxPC-3 cells were treated with
BITC under hypoxia, the HIF-1a and VEGF levels were
significantly reduced (Fig. 3D), confirming the role of STAT-3
in BITC-mediated HIF-1a and VEGF inhibition. Furthermore, in
STAT-3 transiently silenced or permanently knocked out cells,
BITC had little effect on HIF-1a and VEGF expression. Our
results were further confirmed by VEGF ELISA studies in STAT-
3 over-expressing or STAT-3 silenced BxPC-3 cells under hypoxia
(Fig. 3D, right panel). These studies clearly establish the
mechanistic role of STAT-3 in regulating HIF-1a and VEGF in
our model and confirm that the inhibition of HIF-1a and VEGF
by BITC was in fact mediated through STAT-3 inhibition.
BITC inhibits migration and invasion of BxPC-3 cells
Since the migration of endothelial or epithelial cells is one of the
key steps in angiogenesis and metastasis [8], we next explored the
effect of BITC on the migration of BxPC-3 cells in a wound
healing assay. Our results show that 5 mM BITC significantly
blocked the migration of BxPC-3 cells (Fig. 4A). After 36 hours,
about 90% of BxPC-3 cells migrated into the wounded area,
whereas migration of BITC treated cells was around 55%,
indicating a potential anti-migration effect of BITC (Fig. 4B).
We next wanted to see whether BITC inhibits the invasion of
BxPC-3 and PanC-1 cells. Treatment with 10 mM BITC inhibited
around 50% of both BxPC-3 and PanC-1 cell invasion as
compared to untreated cells (Fig. 4C–4D). These results suggest
that BITC may prevent the entry of tumor cells into distal
locations in vivo and thereby inhibit the metastasis of primary
tumors.
Effect of BITC on human endothelial (HUVEC) cells
In a tumor microenvironment, tumor cells secrete VEGF, which
promotes the growth of neighboring endothelial cells. Moreover,
the complex process of angiogenesis involves the ordered
proliferation, assembly, and alignment of endothelial cells [28].
Since we observed that BITC can block VEGF secretion, we next
wanted to see if BITC treatment suppresses the secretion of
angiogenic proteins from human umbilical vein endothelial cells
(HUVEC) through a mechanism similar to what we observed in
BxPC-3 and PanC-1 cells. Our results demonstrate that secretion
of both VEGF and MMP-2 by HUVECs were significantly
inhibited by BITC in a dose-dependent manner (Fig. 5A).
Furthermore, we found that BITC down-regulates the expression
(Fig. 5B) as well as mRNA levels (Fig. 5C) of MMP-2 and
VEGFR-2 in a dose-dependent manner. Consistent with our
observations in BxPC-3 and PanC-1 cells, BITC treatment
significantly increased the expression of RhoB and decreased the
expression of VEGF, RhoA, RhoC, Cdc-42, and Rac1, 2, 3 in
HUVECs (Fig 5B). Interestingly, phosphorylation and DNA
binding activity of STAT-3 was significantly reduced in BITC
treated HUVECs (Fig. 5B & 5D) as compared to control cells.
These results suggest that BITC can suppress the angiogenic
properties of endothelial cells by inhibiting the expression of
proangiogenic proteins. Furthermore, we explored whether BITC
inhibits the migration of HUVECs. Our results show that BITC
treatment significantly blocked the migration/invasion of VEGF-
stimulated HUVECs in a dose-dependent manner (Fig. 5E).
BITC inhibits in vivo pancreatic tumor angiogenesis and
tumor growth
To understand whether BITC directly affects tumor angiogen-
esis, we performed in vivo tumor xenograft experiments in female
athymic nude mice. Our results demonstrate that animals
tolerated BITC well with no symptoms of toxicity such as weight
loss or inactivity was found during BITC administration (data not
given). Furthermore, the treatment of mice with 12 mmol BITC
markedly suppressed BxPC-3 tumor growth as compared to
control group mice (Fig. 6A). In a matrigel plug assay, our results
show a 76% reduction in hemoglobin content in BITC treated
plugs as compared to untreated plugs (Fig. 6B). Similarly, BITC-
treated tumor xenografts showed 61% reduced hemoglobin
content as compared to untreated xenografts (Fig. 6B). To further
explore the mechanism, tumors were analyzed by western blotting.
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25799We observed that phosphorylation of STAT-3 (Tyr-705), VEGR-2
(Tyr-1175) and expression of HIF-a, VEGF, MMP-2, CD31, and
RhoC decreased significantly in the tumors of BITC-treated mice
as compared to the tumors from control mice (Fig. 6C). Taken
together, our in vivo results complement our in vitro results and
clearly indicate the antiangiogenic and antimetastatic potentials of
BITC.
Discussion
Once a tumor reaches a certain size, simple diffusion of oxygen
and nutrients to the growing tumor becomes inadequate; hence,
specialized blood vessel formation (angiogenesis) is required to
meet the increasing demand of nutrition [10]. Angiogenesis is a
complex multi-step process that involves cell proliferation,
migration, and tube formation. Inhibition of new blood vessel
formation leads to a reduced supply of oxygen and nutrients to the
tumor, thereby limiting tumor growth (30). Since the growth of
tumors is dependent on angiogenesis, its inhibition presents a
novel approach to suppressing the growth of solid tumors,
including pancreatic tumors [29]. Our results show that sprouting
of aortic rings as well as new blood vessel formation on CAM was
significantly inhibited by BITC even at sub-lethal concentrations,
providing a critical clue to the ability of BITC to inhibit
angiogenesis. Furthermore, BITC significantly inhibits the inva-
sion and migration of BxPC-3 and PanC-1 cells, both of which are
considered crucial steps in metastasis [8].
In tumor microenvironment, hypoxia stimulates accumulation
of HIF-1a protein by decreasing proteasomal degradation. VEGF
and MMP-2 involved in angiogenesis are up-regulated by HIF-1a
[10,30]. Previous reports have shown that inhibition of HIF-1a
expression leads to decreased tumor growth [31,32]. Our current
results demonstrate that BITC significantly reduces HIF-a
accumulation in hypoxia-induced BxPC-3 and PanC-1 pancreatic
cancer cells.
Matrix metalloproteinases (MMPs) are capable of degrading
numerous matrix components. Several different MMPs are
produced in the tumor microenvironment and are strongly
implicated in the capillary-sprouting process. Amongst other
MMPs, MMP-2 plays a major role in basement membrane
degradation [33,34]. Moreover, MMP-2 production is stimulated
by VEGF [35]. Our results reveal that BITC treatment inhibits
hypoxia-stimulated secretion of VEGF and MMP-2 in both BxPC-
3 and PanC-1 cells. Moreover, BITC also reduces the constitutive
secretion of VEGF and MMP-2, which was independent of HIF-
1a, in normoxic BxPC-3 and PanC-1 cells. These observations
suggest that BITC inhibits tumor cell-secreted proangiogenic
factors by both HIF-a dependent and independent mechanism.
VEGF initially was thought to mediate its signaling in a
paracrine manner by acting on neighboring endothelial cells, but
later it was found that it also acts in an autocrine manner to
promote the growth of tumor cells. Various tumors, including
pancreatic tumors, are known to express VEGF receptor-2
(VEGFR-2). Further, VEGF binds to VEGFR-1 and VEGFR-2
on endothelial cells and stimulates signaling related to angiogenesis
[25]. Our results demonstrate that BITC significantly inhibits
phosphorylation (Tyr-1175) and expression levels of VEGF and
VEGFR-2 in BxPC-3, PanC-1, and HUVEC cells. Moreover,
reduced VEGFR-2 expression was due to decreased transcription
of VEGFR-2, as evidenced by reduced mRNA levels in BITC-
treated cells. Upon VEGF stimulation, VEGFR-2 undergoes
phosphorylation at Tyr-1175, leading to the activation of a
number of downstream signaling cascades, including MAPK,
PI3K, and PLCc.
We recently observed that BITC suppresses in vitro and in vivo
pancreatic tumor cell growth by inhibiting the PI3K/AKT
pathway [36]. Previous studies have shown that the Rho-family
of small GTPases plays an essential role in transmitting the VEGF
signals downstream to angiogenesis [37]. Upon VEGF stimulation,
c-Src is phosphorylated at Tyr-416 and activated Src interacts
with FAK; the Src/FAK complex further activates Rho GTPases
[38]. The super-family of Rho-GTPases consists of various Rho-
specific insertion domains containing subfamilies such as Rho,
Rac, Cdc-42, etc. RhoA and RhoC expression and/or activity
frequently is increased in human tumors, whereas RhoB is down-
regulated in various cancers [16]. Moreover, increased expression
of RhoC correlates with the progression and poor prognosis of
ductal adenocarcinoma of the pancreas [39]. The inhibition of
Rho-GTPases would lead to decreased metastasis.
Our results clearly demonstrate that BITC treatment signifi-
cantly reduced the active-RhoA and RhoC protein levels in a
dose-dependent manner in both cell lines. RhoA has been
implicated in virtually all stages of cancer progression and
metastasis, whereas RhoC is restricted to metastasis [40]. Our
results provide evidence that both RhoA and RhoC are the targets
of BITC in pancreatic cancer cells. Unlike RhoA and RhoC, the
level of active-RhoB protein, which is a tumor suppressor gene
[41], was up-regulated in both BxPC-3 and PanC-1 cells by BITC
treatment. Other Rho-GTPases such as Rac 1, 2, 3 and Cdc-42
are necessary for the generation of lamellipodial protrusions
during the mesenchymal migration [42]. BITC treatment
significantly reduced the expression levels of Rac 1, 2, 3 and
Cdc-42. It is tempting to speculate that BITC may inhibit tumor
cell migration by interfering with actin filament rearrangement
and/or inhibition of lamellipodial formation. However, further
studies are needed to substantiate this assumption.
VEGF-stimulated endothelial cells undergo proliferation, mi-
gration, and invasion, leading to new blood vessel formation.
Hence, to mimic the tumor microenvironment, we evaluated the
effect of BITC on VEGF-treated HUVEC migration, invasion,
Figure 3. BITC suppresses proangiogenic proteins. A. BITC down-regulates expression of HIF-a, VEGFR-2, Rho-GTPase signaling molecules.
BxPC-3 or PanC-1 cells were treated with various concentrations of BITC for 24 h and for HIF-a, cells were exposed to 1% O2 for 12 h. Whole cell
lysates were prepared with urea-CHAPS buffer. Cell lysates were analyzed by SDS-PAGE followed by western blot. B. BITC down-regulates mRNA
levels of VEGFR2 and MMP-2 in BxPC-3 and PanC-1 cells. Cells were treated with different concentrations of BITC and total RNA was isolated with
Trizol. Total RNA was analyzed for the expression levels of VEGFR-2 and MMP-2 by RT-PCR. GAPDH was used as internal control. Quantitative analysis
of mRNA expression levels were performed by Image J software and presented as bar diagram (lower panel) C. BITC inhibits HIF-1a and VEGF
expression by inhibiting phosphorylation of STAT-3. 0.3610
6 cells were plated in 6-well plate and treated with 20 ng/mL IL-6 and 10 mM BITC for
24 h. Cells were analyzed for STAT-3 (Tyr 705), STAT-3, HIF-1a, VEGF, and RhoC expression by western blot. D. STAT-3 is required for BITC mediated
inhibition of HIF-1a and VEGF expression. BxPC-3 cells were transfected with 2 mg of STAT-3a over-expressing plasmid and, in another experiment,
STAT-3 was either transiently silenced or permanently knocked out by shRNA. Transfected cells were treated with or without 10 mM BITC for 24 h
after 48 h of transfection. Cells were lysed and analyzed by western blot. Right panel showing secreted VEGF level was evaluated in STAT-3 over-
expressing or silenced BxPC-3 cells by ELISA as described above. * Values of p,0.01 statistically significant when compared with normoxic controls.
**p,0.01 statistically significant when compared with hypoxic controls. #p,0.01statistically significant when compared with STAT-3 over-expressing
cells.
doi:10.1371/journal.pone.0025799.g003
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e25799Figure 4. BITC inhibits migration and invasion of pancreatic cancer cells. A. BITC inhibits migration of BxPC-3 cells. BxPC-3 cells were plated,
scratched with pipette tip, and incubated in the absence or presence of 5 mM BITC. Photomicrographs were made at regular intervals using inverted
microscope. B. Quantitative representation of migration assay. Wound area in BITC-treated and control cells were quantified by Image J software and
presented as mean 6 SD of triplicates. p,0.01, statistically significant when compared to corresponding time points in controls cells. C–D. BITC
inhibits the invasion of BxPC-3 and PanC-1 cells. Invasion assay was performed using Boyden’s chamber. Results are presented as mean 6 SD of
triplicates. p,0.05, statistically significant when compared controls.
doi:10.1371/journal.pone.0025799.g004
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25799and secretion of proangiogenic factors. Interestingly, BITC down-
regulated the DNA-binding activity and phosphorylation of
STAT-3 (Tyr-705), and Rho-GTPases expression in HUVECs,
indicating that BITC acts on endothelial cells in a similar fashion
as acts on pancreatic epithelial cancer cells. Further, BITC
inhibited HUVEC migration, invasion, and VEGF/MMP-2
secretion, indicating that it specifically targets the angiogenic
ability of HUVECs.
Previous reports have shown a close association between STAT-
3 activation and pancreatic tumor growth and vascularization
[14]. Moreover, activation of STAT-3 has been directly correlated
with HIF-1a and VEGF (14). Our previous investigations have
shown that BITC significantly inhibits the phosphorylation of
STAT-3 at Tyr-705 [23]. Hence, we wanted see whether
inhibiting the phosphorylation of STAT-3 at Tyr-705 would lead
to inhibition of HIF-1a and VEGF expression. In agreement with
previously published studies [12,13], IL-6 treatment significantly
increased phosphorylation of STAT-3, HIF-1a and VEGF
expression as compared to untreated cells. The effect of BITC
on HIF-1a and VEGF expression was significantly diminished in
IL-6 treated cells. Previous studies also have shown that
phosphorylation of STAT-3 at Tyr-705 is required for dimeriza-
tion, translocation, and transcriptional activation of HIF-1a [13].
Since IL-6 is a pleiotropic cytokine which elucidates its cellular
processes by activating not only STAT-3 but also other targets
such as MAPK [43], the association of HIF-1a and VEGF with
STAT-3 in our model was further confirmed by ectopic expression
of STAT-3. As also shown in previous studies, STAT-3 over-
expressing BxPC-3 cells showed a much higher expression of HIF-
1a and VEGF as compared to cells expressing constitutive levels of
STAT-3 under hypoxic conditions [13]. Hypoxia failed to induce
HIF-1a and VEGF expression in STAT-3 silenced or stably
knocked out (KO) BxPC-3 cells, indicating that STAT-3 is
indispensible for hypoxia-induced expression of HIF-1a and
VEGF. When STAT-3 over-expressing BxPC-3 cells were treated
with BITC, hypoxia-induced HIF-1a and VEGF expression were
significantly diminished; whereas, in STAT-3 KO or transiently
silenced cells, BITC caused no change in the expression of HIF-1a
or VEGF, indicating that BITC-mediated down-regulation of
HIF-1a and VEGF was in fact mediated through STAT-3.
To evaluate the anti-angiogenic activity of BITC in vivo, athymic
nude mice were injected with BxPC-3 cells and orally gavaged
with 12 mmol BITC. BITC suppressed the growth of pancreatic
tumor xenografts and also drastically reduced the hemoglobin
content in BITC-treated xenografts or implanted Matrigel plugs.
These results suggest that BITC inhibits tumor growth in vivo not
only by directly inhibiting tumor cell proliferation but also through
inhibiting tumor angiogenesis. Our results clearly demonstrate a
reduced phosphorylation of STAT-3 (Tyr-705), VEGFR-2 (Tyr-
1175), and expression of MMP-2, HIF-a, and Rho-GTPases in the
tumors of BITC-treated mice as compared to the tumors of
control mice. Taken together, our data provides convincing
evidence that BITC inhibits pancreatic tumor angiogenesis by




Human pancreatic cancer cell lines BxPC-3 and PanC-1 were
procured from ATCC (Manassas, VA). BxPC-3 cells have wild
type KRas, whereas PanC-1 cells have mutated KRas (G12D).
PanC-1 cells are more metastatic as compared to BxPC-3 cells.
Both cell lines were maintained as described by us previously [23].
All the antibodies were procured from Cell Signaling Technology
Inc. (Danvers, MA), except HIF-a which was obtained from
Abcam (Cambridge, MA).
Aortic sprouting in matrigel
Aortic spouting assay was performed as previously described
[44]. In brief, 1 mm long rings were excised from rat thoracic
aorta. The rings were submerged in 350 mL Matrigel (BD
Biosciences, Bedford, MA) containing 20 ng/mL VEGF. After
24-hour incubation, BITC was added to the rings and incubated
for an additional 3–5 days. The aortic rings formed microvascular-
like sprouts which were photographed under a light microscope
(Olympus Inc., Center Valley, PA). The results were quantified by
Image J 1.43 software provided by National Institutes of Health
(NIH).
Chicken chorioallantoic membrane (CAM) assay
The CAM assay was performed according to the method
described by Tournaire, et al. [45]. Fertilized chicken eggs were
obtained from Charles River Laboratories (Wilmington, MA) and
kept at room temperature for 48 hours. On the 4
th day at a
temperature of 37uC, a 1.5–2 cm window was opened aseptically
on each egg shell, exposing the part of the CAM which contained
the central vein. The windows were then sealed with sterile
Parafilm and the eggs were returned to the incubator for 24 hours.
On day 6 of incubation, a Whatman filter paper disc containing
5 mmol BITC was placed in direct contact with the CAM. The
windows were again sealed and returned to the incubator. On day
9-12, the seals were removed and neovasculature growth on CAM
was photographed with a digital camera (Nikon Inc, Melville, NY).
Estimation of MMP-2 and VEGF secretion by ELISA
Secreted MMP-2 and VEGF levels in BITC treated BxPC-3
culture medium were measured using an ELISA kit (Invitrogen
Corp., Carlsbad, CA) according to manufacturer instructions.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from control and treated cells using
TRIzol reagent (Life Technologies, Inc., Carlsbad, CA) according
to manufacturer instructions. Amplification was performed using
Figure 5. BITC inhibits angiogenesis in HUVECs. A. BITC inhibits the secretion of proangiogenic factors from HUVECs. Cells were plated,
stimulated with VEGF, and treated with BITC for 24 h. Media was collected and assayed for MMP-2 and VEGF by ELISA kit. *p,0.01 statistically
significant when compared with controls. #p,0.01 statistically significant when compared with VEGF-stimulated controls. B. Regulation of VEGF
mediated signaling by BITC. HUVECs were treated with various concentrations of BITC and whole cell lysates were analyzed by western blot. C. BITC
down-regulates VEGFR2 and MMP-2 mRNA in HUVECs. Total RNA from BITC-treated HUVECs was isolated with Trizol and analyzed for the expression
levels of VEGFR-2 and MMP-2 by RT-PCR. GAPDH was used as internal control. mRNA expression levels were quantified by Image J software and
presented as bar diagram (lower panel). D. BITC inhibits STAT-3 DNA binding activity in HUVECs. HUVECs were treated with BITC and nuclear fraction
was collected. Around 5 mg of nuclear protein subjected to STAT-3 DNA binding activity by Universal EZ-TFA transcription factor assay colorimetric kit
according to the manufacturer’s protocol. #p,0.01 statistically significant when compared with controls. E. BITC inhibits invasion of HUVECs.
Invasion assay was performed using Boyden’s chamber. *p,0.01 statistically significant when compared with controls. #p,0.01 statistically
significant when compared with VEGF-stimulated controls
doi:10.1371/journal.pone.0025799.g005
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MMP-2 sense and antisense primers 59-GTG CTG AAG GAC
ACA CTA AAG AAG A-39 and 59-TTG CCA TCC TTC TCA
AAG TTG TAG G-39, respectively. VEGFR-2 primers were
procured from R&D Systems, Inc. (Minneapolis, MN). PCR
amplification consisted of 35 cycles with denaturation at 94uC for
1 minute, annealing at 58uC for 1 minute and extension at 72uC
for 1 minute, and a final elongation at 72uC for 10 minutes. The
PCR products were separated on a 1.5% agarose gel, stained with
0.5 mg/mL ethidium bromide, and visualized under UV light.
STAT-3 DNA binding activity
Cells were treated with various concentrations of BITC for 24 h
and nuclear fraction was isolated. Around 5 mg of nuclear protein
was subjected to STAT-3 DNA binding activity using Universal
EZ-TFA transcription factor assay colorimetric kit (Upstate
Biotechnology, Inc, Lake Placid, NY) as described by us earlier
[22].
Induction of STAT-3 mediated HIF-1a expression by IL-6
treatment
STAT-3-mediated HIF-1a expression was induced as described
earlier, with minor modifications [13]. Briefly, 0.3610
6 BxPC-3
cells were plated in a 6-well plate overnight and treated with or
without 10 mM BITC in the presence or absence of 20 ng/mL IL-
6 for 24 hours. Cells were collected, lysed, and analyzed by
western blotting.
Over expression or silencing of STAT-3
Plasmid containing STAT-3a was transfected in BxPC-3 cells to
over-express STAT-3 as previously described [23]. To silence
STAT-3, BxPC-3 cells pre-incubated in Opti-MEM medium were
transfected with 1.5 mg/ml of STAT-3 shRNA using SiPORT
transfection reagent (Ambion, Inc, Carlsbad, CA). After 48 hours
of transfection, cells were treated with or without 10 mM BITC for
24 hours under hypoxic conditions.
Generation of STAT-3 knock out BxPC-3 cells
STAT-3 was stably silenced in BxPC-3 cells using a shRNA kit
from SA Biosciences (Frederick, MD). Briefly, BxPC-3 cells were
transfected with STAT-3 shRNA using lipofectamine and allowed
to grow according to manufacturer’s instructions. Stable selections
were made in the presence of G418. Surviving transfected cells
were grown in the presence of 100 mg/ml G418 for at least five
passages before using them for any experiment. We were able to
silence about 85% of STAT-3 expression in these cells.
Wound healing and transwell migration assay
Wound healing assay was performed as described earlier [46].
Confluent monolayers of BxPC-3 cells in 6-multiwell plates were
scratched with a 1 mL pipette tip and incubated in RPMI medium
containing 5 mM BITC. Cells were photographed under a
microscope (Olympus America, Inc, Center Valley, PA) at the
intervals of 0, 12, 24, 36 and 48 hours. Results were quantified by
Image J 1.43 software (NIH). Cell invasion was performed in
Transwell Boyden chamber containing 8.0 mm pore size filters
(BD Biosciences, Bedford, MA). Briefly, cells were serum starved
overnight and harvested by tripsinization. A suspension of 20,000
cells in RPMI medium (600 mL) containing 1% serum were seeded
on the upper well of Boyden chamber while lower chamber was
filled with 1.5 mL of media with 1% serum. After incubation for
6 h, cells were pre-treated with 10 mM mitomycin C for 1 h and
then BITC was added to upper chamber whereas, 10% FBS and
20 ng/mL HGF/VEGF was added to lower chamber as a chemo-
attractant. After incubation for 24 h, cells on the upper surface
were removed by wiping with a cotton swab. The filters containing
the cells were removed from the Transwell chambers and
individually transferred to separate wells in a 96-well plate and
developed as described by the manufacturer.
Western blot analysis
Treated and untreated BxPC-3/PanC-1 cells were washed
twice with PBS, lysed, and subjected to western blot analysis as
previously described by us [22].
In Vivo tumor xenograft assay
All the experiments involving animals were approved by the
Institutional Animal Care and Use Committee (IACUC), Texas
Tech University Health Sciences Center and the experiments were
conducted in strict compliance and regulations. Twenty 4–8 week
old female athymic nude mice (Charles River, Wilmington, MA)
were kept on an antioxidant-free AIN-76A diet (TestDiet,
Richmond, IN) for 1 week before starting the experiment. About
1610
6 exponentially growing BxPC-3 cells were injected subcu-
taneously into the left and right flanks so that each mouse had two
xenografts. Tumor volumes were measured three times a week
[22]. Once each mouse had palpable tumors, mice were randomly
separated into two groups of 10 mice each. Mice in the
experimental group received 12 mmol BITC by oral gavage every
day, whereas the control mice received vehicle alone. At the end of
the experiment, mice were sacrificed humanely by in accordance
with IACUC guidelines; tumors were excised from each mouse
and snap frozen.
Matrigel plug assay
Matrigel plug assay was performed as described earlier [44]. A
Matrigel (BD Biosciences, Bedford, MA) mixture (250 mL)
containing 40 ng/ml VEGF was injected subcutaneously into 4–
8-week-old female athymic nude mice (n=10) on both flanks. The
mice were daily gavaged with 12 mmol BITC for 7 days, after
which they were euthanized and the matrigel plugs were
recovered. The plugs were dispersed in PBS and incubated at
37uC overnight. Hemoglobin levels were determined using
Drabkin’s reagent (Sigma-Aldrich, St. Louis, MO) according to
manufacturer instructions.
Hypoxia treatment
For hypoxia treatment, cells were treated with various
concentrations of BITC for 24 hours and then exposed to hypoxic
conditions (1% O2) for 12 hours in drug-free hypoxic media. The
Figure 6. BITC inhibits in vivo tumor growth by inhibiting proangiogenic proteins. A. BITC suppresses tumor growth in vivo. BxPC-3
xenografts bearing mice (n=10) were orally fed with 12 mmol BITC daily for 40 days. Right side panel shows photographs of isolated tumors from
control and BITC-treated mice. B. BITC inhibits tumor angiogenesis. BxPC-3 xenografts or matrigel plug-bearing mice were fed with 12 mmol BITC
daily for 40 or 7 days, respectively. Tumors and plugs were collected and 50 mg of tumor or plugs were analyzed for hemoglobin content by
Drabkin’s reagent. C. BITC down-regulates pro-angiogenic proteins in tumor xenografts. Cell lysates were prepared from isolated tumor xenografts,
subjected to western blot and analyzed for VEGFR-2, MMP-2, HIF-a, and Rho-GTPases D. Quantitative analysis of tumor western blots. *p,0.01
statistically significant when compared with controls.
doi:10.1371/journal.pone.0025799.g006
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subjected to western blot analysis.
Statistical analysis
All the statistical analyses were performed using Prism 5.0
(GraphPad Software Inc., San Diego, CA). Results were expressed
as mean 6 SD or S.E.M. for at least three independent
experiments. Data were analyzed by Student’s t-test or one way
ANOVA followed by Bonferroni’s post-hoc analysis for multiple
comparisons. Differences were considered statistically significant at
p,0.05.
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